CompanyGraph
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
688505 · SSE · China
fd-zj.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.32B, above the global median of $1.18B
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.84BCNY1.32B · vs all stocks (USD)
Revenue (TTM)
667.94MCNY99.70M · vs all stocks (USD)
Profit Margin
-18.90%Beta
0.0910xvs all stocks
52-Week Change
-7.83%vs all stocks
Market Capitalization
8.84BCNY1.32B · vs all stocks (USD)
Enterprise Value
6.80BCNY1.02B · vs all stocks (USD)
Price to Sales (TTM)
12.07xPrice to Book (MRQ)
3.72xEnterprise to Revenue
10.18xEnterprise to EBITDA
-80.16xProfit Margin
-18.90%Operating Margin
8.86%Return on Assets (TTM)
-3.37%Return on Equity (TTM)
-5.71%Revenue (TTM)
667.94MCNY99.70M · vs all stocks (USD)
Revenue per Share (TTM)
0.6440CNYUpdated Sep 22, 2026Quarterly Revenue Growth
6.20%Gross Profit (TTM)
605.89MCNY90.44M · vs all stocks (USD)
EBITDA (TTM)
-84.86MCNY-12.67M · vs all stocks (USD)
Net Income (TTM)
-126.26MCNY-18.85M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
856.80%Operating Cash Flow (TTM)
161.81MCNY24.15M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
144.66MCNY21.59M · vs all stocks (USD)
5-Year Average Dividend Yield
0.71%vs all stocks
Payout Ratio
234.79%Minority Interest (Equity)
425.61KCNYFY2025 · Dec 31, 2025Revenue
685.80MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
69.31MCNYFY2025 · Dec 31, 2025Gross Profit
616.49MCNYFY2025 · Dec 31, 2025Operating Income
-170.35MCNY-25.43M · vs all stocks (USD)
Pre-tax Income
-155.85MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.87MCNYFY2025 · Dec 31, 2025Net Income
-157.72MCNYFY2025 · Dec 31, 2025EBIT
-155.19MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-105.02MCNYFY2025 · Dec 31, 2025Research & Development
357.94MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
280.17MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.74MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.81MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
662.89KCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
-157.72MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
284.08KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
79.61MCNYFY2025 · Dec 31, 2025Free Cash Flow
48.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.15BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-157.72MCNYFY2025 · Dec 31, 2025Other Non-cash Items
6.54MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
213.27MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
17.53MCNYFY2025 · Dec 31, 2025Capital Expenditures
-31.54MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.29BCNYFY2025 · Dec 31, 2025Sale of Investments
3.30BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-12.21MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-31.10MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-31.10MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.04BSharesUpdated Sep 22, 2026Float Shares
437.20MSharesUpdated Sep 22, 2026% Held by Insiders
60.54%vs all stocks
% Held by Institutions
0.33%vs all stocks
Total Cash (MRQ)
1.22BCNY182.56M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.18CNYUpdated Sep 22, 2026Total Debt (MRQ)
11.99MCNY1.79M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0056xCurrent Ratio (MRQ)
6.53xBook Value per Share (MRQ)
2.08CNYUpdated Sep 22, 2026Total Assets
2.39BCNY356.85M · vs all stocks (USD)
Total Current Assets
1.49BCNYFY2025 · Dec 31, 2025Total Liabilities
273.93MCNYFY2025 · Dec 31, 2025Total Non-current Assets
905.13MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
28.31MCNYFY2025 · Dec 31, 2025Total Current Liabilities
245.62MCNYFY2025 · Dec 31, 2025Cash
1.15BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.15BCNYFY2025 · Dec 31, 2025Accounts Receivable
201.34MCNYFY2025 · Dec 31, 2025Inventory
33.21MCNYFY2025 · Dec 31, 2025Accounts Payable
6.07MCNYFY2025 · Dec 31, 2025Short-term Debt
5.35MCNYFY2025 · Dec 31, 2025Long-term Debt
9.34MCNYFY2025 · Dec 31, 2025Common Stock (Book)
103.66MCNYFY2025 · Dec 31, 2025Retained Earnings
676.22MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.12BCNY315.96M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
6.58CNYUpdated Sep 22, 202652-Week High
9.50CNYUpdated Sep 22, 202652-Week Change
-7.83%vs all stocks
Beta
0.0910xvs all stocks
50-Day MA
7.86CNYUpdated Sep 22, 2026200-Day MA
7.99CNYUpdated Sep 22, 2026Avg 10-Day Volume
4.66MSharesUpdated Sep 22, 2026Avg 30-Day Volume
10.67MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.1200CNYUpdated Sep 22, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.32B, above the global median of $1.18BNotable
Market cap (USD): 1,320,239,412.8Global Median: 1,180,223,658.953
Levered free cash flow is $21.59M, above the global median of $18.73MNotable
Levered free cash flow (USD): 21,594,059.765Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bio-Thera Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
North China Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Skyworks Solutions Inc.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease
Forward Industries, Inc.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease
Maccura Biotechnology Co., Ltd.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease